Moderna and Merck cancer vaccine cuts melanoma recurrence risk by 42%
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Moderna and Merck’s personalized mRNA vaccine, intismeran autogene, reduced melanoma patients’ risk of disease recurrence by 42% versus standard treatment in a large trial. The individualized therapy targets neoantigens unique to each patient’s tumor.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu